Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Non-cash Items (2020 - 2022)

Ovid Therapeutics (OVID) has disclosed Non-cash Items for 3 consecutive years, with $3.1 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Non-cash Items fell 52.29% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Mar 2022, down 52.29%, and an annual FY2021 reading of $2.4 million, up 266.3% over the prior year.
  • Non-cash Items was $3.1 million for Q1 2022 at Ovid Therapeutics, up from $2.4 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $18.2 million in Q2 2020 and bottomed at $652438.0 in Q4 2020.
  • Average Non-cash Items over 3 years is $5.8 million, with a median of $3.1 million recorded in 2022.
  • Peak annual rise in Non-cash Items hit 266.3% in 2021, while the deepest fall reached 71.26% in 2021.
  • Year by year, Non-cash Items stood at $652438.0 in 2020, then soared by 266.3% to $2.4 million in 2021, then grew by 28.84% to $3.1 million in 2022.
  • Business Quant data shows Non-cash Items for OVID at $3.1 million in Q1 2022, $2.4 million in Q4 2021, and $3.0 million in Q3 2021.